S&P 500   3,258.59 (+0.37%)
DOW   26,853.30 (+0.14%)
QQQ   268.10 (+1.02%)
AAPL   110.19 (+1.82%)
MSFT   206.09 (+1.43%)
FB   251.08 (+0.62%)
GOOGL   1,425.01 (+0.15%)
AMZN   3,040.33 (+0.68%)
TSLA   404.70 (+4.36%)
NVDA   504.21 (+2.08%)
BABA   267.34 (-0.89%)
CGC   14.00 (-1.89%)
GE   6.03 (-0.50%)
MU   48.34 (-2.28%)
AMD   76.44 (+0.82%)
T   27.77 (-0.96%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.59 (+0.74%)
DIS   122.22 (-0.22%)
BAC   23.22 (-0.51%)
BA   150.71 (+3.19%)
S&P 500   3,258.59 (+0.37%)
DOW   26,853.30 (+0.14%)
QQQ   268.10 (+1.02%)
AAPL   110.19 (+1.82%)
MSFT   206.09 (+1.43%)
FB   251.08 (+0.62%)
GOOGL   1,425.01 (+0.15%)
AMZN   3,040.33 (+0.68%)
TSLA   404.70 (+4.36%)
NVDA   504.21 (+2.08%)
BABA   267.34 (-0.89%)
CGC   14.00 (-1.89%)
GE   6.03 (-0.50%)
MU   48.34 (-2.28%)
AMD   76.44 (+0.82%)
T   27.77 (-0.96%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.59 (+0.74%)
DIS   122.22 (-0.22%)
BAC   23.22 (-0.51%)
BA   150.71 (+3.19%)
S&P 500   3,258.59 (+0.37%)
DOW   26,853.30 (+0.14%)
QQQ   268.10 (+1.02%)
AAPL   110.19 (+1.82%)
MSFT   206.09 (+1.43%)
FB   251.08 (+0.62%)
GOOGL   1,425.01 (+0.15%)
AMZN   3,040.33 (+0.68%)
TSLA   404.70 (+4.36%)
NVDA   504.21 (+2.08%)
BABA   267.34 (-0.89%)
CGC   14.00 (-1.89%)
GE   6.03 (-0.50%)
MU   48.34 (-2.28%)
AMD   76.44 (+0.82%)
T   27.77 (-0.96%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.59 (+0.74%)
DIS   122.22 (-0.22%)
BAC   23.22 (-0.51%)
BA   150.71 (+3.19%)
S&P 500   3,258.59 (+0.37%)
DOW   26,853.30 (+0.14%)
QQQ   268.10 (+1.02%)
AAPL   110.19 (+1.82%)
MSFT   206.09 (+1.43%)
FB   251.08 (+0.62%)
GOOGL   1,425.01 (+0.15%)
AMZN   3,040.33 (+0.68%)
TSLA   404.70 (+4.36%)
NVDA   504.21 (+2.08%)
BABA   267.34 (-0.89%)
CGC   14.00 (-1.89%)
GE   6.03 (-0.50%)
MU   48.34 (-2.28%)
AMD   76.44 (+0.82%)
T   27.77 (-0.96%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.59 (+0.74%)
DIS   122.22 (-0.22%)
BAC   23.22 (-0.51%)
BA   150.71 (+3.19%)
Log in
NASDAQ:CRNX

Crinetics Pharmaceuticals Stock Forecast, Price & News

$14.48
+0.44 (+3.13 %)
(As of 09/25/2020 11:27 AM ET)
Add
Compare
Today's Range
$13.94
Now: $14.48
$14.64
50-Day Range
$13.62
MA: $15.35
$17.02
52-Week Range
$10.63
Now: $14.48
$26.67
Volume1,940 shs
Average Volume141,168 shs
Market Capitalization$476.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.19
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing's diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Read More
Crinetics Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRNX
CUSIPN/A
CIKN/A
Phone858-450-6464

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.19 million
Book Value$4.84 per share

Profitability

Net Income$-50,420,000.00

Miscellaneous

Employees47
Market Cap$476.16 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$14.48
+0.44 (+3.13 %)
(As of 09/25/2020 11:27 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

How has Crinetics Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRNX shares have decreased by 6.6% and is now trading at $14.48.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Crinetics Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Crinetics Pharmaceuticals
.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Crinetics Pharmaceuticals
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) released its quarterly earnings data on Friday, August, 7th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.02.
View Crinetics Pharmaceuticals' earnings history
.

What price target have analysts set for CRNX?

3 brokerages have issued 12 month price objectives for Crinetics Pharmaceuticals' shares. Their forecasts range from $30.00 to $38.00. On average, they anticipate Crinetics Pharmaceuticals' share price to reach $35.00 in the next year. This suggests a possible upside of 141.7% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals
.

Who are some of Crinetics Pharmaceuticals' key competitors?

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the following people:
  • Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 57)
  • Mr. Marc J. C. Wilson, CFO & Sec. (Age 40)
  • Dr. Alan S. Krasner, Chief Medical Officer (Age 56)
  • Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 53)

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (14.98%), Perceptive Advisors LLC (11.13%), Orbimed Advisors LLC (8.37%), Versant Venture Management LLC (6.18%), 5AM Venture Management LLC (4.15%) and Driehaus Capital Management LLC (2.70%). Company insiders that own Crinetics Pharmaceuticals stock include Matthew K Fust, Richard Scott Struthers, Ventures Iv LP 5Am, Vivo Capital Fund Viii, LP and Vivo Capital Viii, Llc.
View institutional ownership trends for Crinetics Pharmaceuticals
.

Which institutional investors are selling Crinetics Pharmaceuticals stock?

CRNX stock was sold by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, and Jacobi Capital Management LLC. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Matthew K Fust, Richard Scott Struthers, and Vivo Capital Viii, Llc.
View insider buying and selling activity for Crinetics Pharmaceuticals
.

Which institutional investors are buying Crinetics Pharmaceuticals stock?

CRNX stock was purchased by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, FMR LLC, Perceptive Advisors LLC, Driehaus Capital Management LLC, Orbimed Advisors LLC, Point72 Asset Management L.P., Bank of New York Mellon Corp, and Nuveen Asset Management LLC.
View insider buying and selling activity for Crinetics Pharmaceuticals
.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $14.48.

How big of a company is Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals has a market capitalization of $476.16 million and generates $1.19 million in revenue each year. The company earns $-50,420,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.